Yes—very high levels of this blood marker were linked to a 38% risk of developing thinking problems within five years. The marker was p-tau217 (Alzheimer's Risk Marker), which reflects early brain changes linked to Alzheimer's disease. The 2026 JAMA study combined data from 2,684 older adults across six groups. They lived in North America, Japan, and Australia. None had measured thinking problems at the start. The middle age was about 70, and 63% were women. Researchers compared starting blood levels with later changes in thinking skills. The middle follow-up time was 5.4 years. During follow-up, 478 people developed thinking problems, ranging from mild changes to dementia. Five-year risk was 24% in the high group and 38% in the very high group. Higher starting levels also lined up with faster declines on thinking tests. Risk rose further over 10 years, but fewer long-term records made those estimates less certain. These results describe risk, not a fixed future. Most people in the very high group did not develop thinking problems within five years. The groups were selected for studies, rather than drawn from the general public. That limits how closely these estimates may fit any one member. For BioSocial members tracking this marker, the key distinction is starting level versus change. This study linked a starting result to later outcomes. It did not show that lowering the number prevents decline. Sharing results alongside test dates and follow-up experiences can help the community compare notes without treating a group estimate as a personal forecast. What has tracking this marker helped you understand, and what questions remain about your numbers?